Which statement correctly contrasts regulatory pathways for biologics and small molecules in the U.S.?

Prepare for the Drug Discovery and Healthcare Systems Test. Access flashcards and multiple-choice questions with hints and explanations. Ace your exam with our comprehensive resources!

Biologics and small molecules follow different regulatory tracks in the United States, reflecting their distinct nature. Biologics are regulated under the Public Health Service Act, and their licensing path is a Biologics License Application that FDA’s Center for Biologics Evaluation and Research evaluates. This setup exists because biologics—typically produced from living systems—require specialized review tailored to their production and characterization. Small molecules are regulated under the Federal Food, Drug, and Cosmetic Act, with a typical licensing path through a New Drug Application reviewed by FDA’s Center for Drug Evaluation and Research. The statement aligns with this structure, correctly naming the Public Health Service Act, the Biologics License Application, and the Center for Biologics Evaluation and Research. The other choices misstate either the governing act, the licensing pathway, or the FDA center involved.